Searched for
BIOPHARMACEUTICAL BUSINESSES
Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...- Why the world is betting on China again, and what India must do about itChina's business environment prioritizes market share with strong government backing. The nation has shifted to high-quality, high-speed pr...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- US stock market today: why Dow Jones crashing big while S&P 500 and Nasdaq are rising? Dow down by 200 points as oil surge, Fed jitters, and Big Tech earnings split market directionUS stock market today: Why Dow Jones Industrial Average falls while S&P 500 and Nasdaq Composite hold steady? US stock market today shows a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- Pfizer reviewing alternatives for consumer healthcare businessPfizer consumer healthcare develops, manufactures and markets leading non-prescription medicines, vitamins, and personal care products.
- GE Healthcare to acquire PAA LaboratoriesGE Healthcare said that it has reached an agreement to acquire PAA Laboratories that develops and supplies cell culture media for biomedica...
- Samsung Group, Quintiles to form drug ventureSamsung Electronics, the world's biggest manufacturer of flat screen televisions and computer memory chips, will hold 40 per cent of the ve...
- Licensing deals help Biocon post healthy Q3 nosBiocon's third quarter consolidated net profit rose 24% to 100.75 helped by inflows from licensing deals with global biggies Pfizer and Myl...
- Biocon acquires 49% Cuban partner CIMAB’s stake in JVBiocon has fully acquired the joint venture Biocon Biopharmaceuticals from its Cuban partner CIMAB.
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
Load More
